SeaStar Medical announced that the U.S. Food and Drug Administration (FDA) has confirmed the company has fulfilled its post-approval study requirements for the QUELIMMUNE therapy. This therapy is used to treat pediatric patients with life-threatening acute kidney injury (AKI) associated with sepsis. The fulfillment of these requirements is expected to expand patient access by removing the need for hospitals to have the specific research infrastructure previously required to participate in the study registry.
Key Details
- Regulatory Milestone: The FDA determined that the QUELIMMUNE Pediatric SAVE Surveillance Registry has fulfilled the post-approval study requirements outlined in the original Humanitarian Device Exemption (HDE) approval.
- Expanded Market Access: Hospitals can now use the QUELIMMUNE therapy without the extensive research infrastructure the registry demanded, potentially increasing adoption and availability for critically ill children.
- Supporting Clinical Data: Recent data presented from the registry showed a statistically significant improvement in 90-day survival of 65.1% for patients treated with QUELIMMUNE, compared to 47.5% for patients in control cohorts.